Cizzle Biotechnology Holdings Plc
CIZ.L · LSE
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | 0.00 | 0.00 | 13.80 |
| FCF Yield | -5,417.68% | -1.95% | -0.00% | -0.00% |
| EV / EBITDA | 0.00 | 0.00 | -2.09 | -5.33 |
| Quality | ||||
| ROIC | 312.76% | -1,064.98% | -52.40% | -33.91% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.90 | 0.16 | 0.17 | 0.24 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -277,400.00% | 49.58% | 23.72% | 99.90% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | 0.17 | 0.11 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |